![]() |
市場調查報告書
商品編碼
1684650
CAR-T 細胞療法市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測CAR T-cell Therapy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
2024 年全球 CAR-T 細胞療法市場價值為 43 億美元,預計將經歷強勁的成長軌跡,2025 年至 2034 年的複合年成長率將達到 30.5%。嵌合抗原受體 (CAR) T 細胞療法正在徹底改變癌症治療,標誌著腫瘤學的一個重要里程碑。這種先進的免疫療法涉及對患者 T 細胞進行基因改造,以便更好地瞄準和消滅癌細胞。 CAR T 細胞療法不僅為患者帶來了新的希望,也改變了我們治療某些癌症的方式。隨著技術的日益普及和進步,這個市場有望不斷擴張。
全球市場分為幾種主要產品,包括 Abecma、Breyanzi、Carvykti、Kymriah、Tecartus、Yescarta 等。其中,Yescarta脫穎而出,成為市場領導者,2024年佔了32.5%的市佔率。 Yescarta佔據市場主導地位的主要原因在於它對B細胞淋巴瘤患者已被證明有效,特別是在傳統治療方法往往無效的複發或難治性病例中。隨著越來越多的患者尋求治療惡性癌症的替代療法,對 Yescarta 的需求持續成長,進一步鞏固了其在該領域的領先地位。
市場範圍 | |
---|---|
起始年份 | 2024 |
預測年份 | 2025-2034 |
起始值 | 43億美元 |
預測值 | 611億美元 |
複合年成長率 | 30.5% |
從適應症來看,CAR-T 細胞治療市場分為白血病、淋巴瘤、多發性骨髓瘤等,其中淋巴瘤的收入最高,2024 年將達到 24 億美元。瀰漫性大 B 細胞淋巴瘤 (DLBCL) 是一種常見的非何杰金氏淋巴瘤,是這一成長的主要貢獻者。 DLBCL 在接受傳統療法治療後復發率較高,這推動了對 CAR T 細胞療法的需求,這種療法在針對和治療侵襲性淋巴瘤方面表現出了顯著的療效。因此,CAR-T 細胞療法越來越被視為治療這些棘手癌症類型的重要解決方案,為別無選擇的患者帶來了新的希望。
預計到 2034 年,美國 CAR-T 細胞療法市場規模將達到 250 億美元,在支持性監管框架的推動下,市場將實現強勁成長。美國食品藥物管理局(FDA)在 CAR-T 細胞療法的快速開發和商業化中發揮了關鍵作用,透過突破性療法認定、孤兒藥地位和快速通道等加速核准流程提供關鍵的監管支持。這些措施加速了CAR-T細胞療法的普及,確保需要救命治療的患者能夠及時獲得治療。
The Global CAR T-Cell Therapy Market, valued at USD 4.3 billion in 2024, is projected to experience a robust growth trajectory, with an impressive CAGR of 30.5% from 2025 to 2034. Chimeric Antigen Receptor (CAR) T-cell therapy is revolutionizing cancer treatment, marking a significant milestone in oncology. This advanced form of immunotherapy involves the genetic modification of a patient's T-cells to better target and eliminate cancer cells. CAR T-cell therapy is not only offering new hope for patients but also changing the way we approach the treatment of certain cancers. With its growing adoption and advancements in technology, this market is poised for continuous expansion.
The global market is divided into several key products, including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and others. Among these, Yescarta stands out as the market leader, capturing 32.5% of the total market share in 2024. The primary reason for Yescarta's market dominance lies in its proven effectiveness for patients with B-cell lymphomas, particularly in relapsed or refractory cases where traditional treatments often fall short. As more patients seek alternatives for aggressive forms of cancer, the demand for Yescarta continues to grow, further cementing its leadership in the space.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $4.3 Billion |
Forecast Value | $61.1 Billion |
CAGR | 30.5% |
In terms of indications, the CAR T-cell therapy market is categorized into leukemia, lymphoma, multiple myeloma, and others, with lymphoma generating the highest revenue of USD 2.4 billion in 2024. Diffuse large B-cell lymphoma (DLBCL), a common form of non-Hodgkin lymphoma is a major contributor to this growth. DLBCL's high relapse rates following conventional therapies have driven demand for CAR T-cell treatments, which have shown remarkable efficacy in targeting and treating aggressive lymphoma. As a result, CAR T-cell therapies are increasingly viewed as a vital solution in managing these challenging cancer types, offering new hope to patients with few options left.
The U.S. CAR T-cell therapy market is expected to reach USD 25 billion by 2034, with strong growth fueled by supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has played a key role in the rapid development and commercialization of CAR T-cell therapies, providing critical regulatory support through expedited approval processes such as Breakthrough Therapy Designations, Orphan Drug status, and Fast Track pathways. These initiatives have fast-tracked the availability of CAR T-cell therapies, ensuring timely access for patients in need of life-saving treatments.